Rationale Dopamine D3 receptor-preferring ligands may be able to modify the conditioned reinforcing effects of drugassociated stimuli. In evaluating the effects of these compounds, it is important to clarify the extent to which responding depends on (1) conditioned reinforcement vs. other behavioral mechanisms and (2) dopamine D3 vs. D2 receptor activity. Objectives To use behaviorally stringent new-response acquisition procedures to characterize the effects of the D3-preferring agonist, pramipexole, on the conditioned reinforc-
Drug-associated environmental stimuli are thought to contribute not only to the compulsive drug-seeking and drug-taking behaviors that are hallmarks of drug abuse and dependence but also to the chronic, relapsing nature of these disorders (e.g., Hogarth et al. 2013; Koob and Le Moal 2008, Table 1 ; Milton and Everitt 2010; Robinson and Berridge 2003; See 2005; Taylor et al. 2009 ). Even compared with other effects of Pavlovian drug-conditioned stimuli (e.g., Pavlovian conditioned approach, Pavlovian-to-instrumental transfer; Milton and Everitt 2010) , conditioned reinforcement may exert especially robust control over behavior (Di Ciano and Everitt 2004 ; see also Taylor et al. 2009; Robinson et al. 2014) . Drug-conditioned reinforcement can enhance both the persistence and diversity of drug-related behavior by maintaining responding over extended periods in the absence of the drug itself and by influencing other, novel types of behavior that had not previously been associated with drug (Bertz and Woods 2013; Di Ciano and Everitt 2004; Palmatier et al. 2007 ). More broadly, conditioned reinforcement can support responses made contrary to primary reinforcement contingencies (Pears et al. 2003) , which may allow drug-related behaviors to continue despite the presence of alternative, non-drug reinforcers, and behavior maintained by a conditioned reinforcer can persist after the primary reinforcer that originally established it has been devalued (Burke et al. 2007; Robinson et al. 2014) . Although the techniques advocated may vary (e.g., Peck and Ranaldi 2014; Troisi 2013) , attenuating the effects of drug-associated stimuli is widely recognized as an important goal in treating drug abuse and dependence (Milton and Everitt 2010; Myers and Carlezon 2010; Taylor et al. 2009 ). Characterizing precisely the environmental and pharmacological factors that determine the conditioned reinforcing effects of drug-associated stimuli may, therefore, facilitate the development of refined treatment interventions.
Several researchers have suggested that dopamine D3-preferring ligands can modify the conditioned reinforcing effects of drug-associated stimuli (Cervo et al. 2003 (Cervo et al. , 2007 Collins et al. 2012; Di Ciano et al. 2003; Gál and Gyertyán 2006; Le Foll et al. 2005; Pilla et al. 1999 ). This idea has been supported by studies of drug selfadministration under second order schedules of reinforcement (Di Ciano et al. 2003; Pilla et al. 1999 ) and of the extinction of drug self-administration responding (Cervo et al. 2003 (Cervo et al. , 2007 Collins et al. 2012; De Vries et al. 2002; Dias et al. 2004; Fuchs et al. 2002; Gál and Gyertyán 2006; Gilbert et al. 2005; Self et al. 1996) . In both of these procedures, D3-preferring agonists increased, and D3-preferring antagonists decreased, responding that produced drug-associated stimuli, but not drug itself. These results are consistent with changes in the conditioned reinforcing effects of the stimuli. However, both responding under second-order schedules of reinforcement and the extinction of a previously trained response can be affected by a number of associative and nonassociative processes other than conditioned reinforcement: the primary reinforcing effects of the training drug; the discriminative stimulus effects of the training drug, the test drug (i.e., the D3-preferring ligand), and the exteroceptive stimuli themselves; and generalization decrements between training and testing conditions, which can have a variety of causes (Collins et al. 2012; Mackintosh 1974; Schindler et al. 2002; Wike 1966, § 1.4; Williams 1994) . In short, it is possible for stimulus presentations to change behavior in these procedures, yet for the stimuli to have no conditioned reinforcing effects at all (Kelleher and Gollub 1962; Wike 1966; Williams 1994) , and so it is difficult to use them to make strong conclusions about the effects of D3-preferring ligands on drug-conditioned reinforcement.
To provide a behaviorally selective test for drug-conditioned reinforcement, the present study characterized the effects of the D3-preferring agonist, pramipexole, on rats' acquisition of a new response for a stimulus paired with the potent, short-acting opioid agonist, remifentanil. To establish a new response with drug-conditioned reinforcement (e.g., Bertz and Woods 2013) , animals are first given response-independent injections of drug and presentations of an exteroceptive stimulus, such that there either is or is not a consistent drug-stimulus pairing. Then, the animals are given access to novel instrumental responses that either do or do not produce the stimulus alone (i.e., without the drug), and the ability of the animals to learn to make the response that produces the stimulus is assessed. These procedures provide a valid measure of conditioned reinforcement (Mackintosh 1974; Williams 1994) : the response that produces the stimulus does not and did not also produce the primary reinforcer, and the behavior generated by stimulus presentation can be shown to depend on both (1) the Pavlovian contingency between the primary reinforcer and the stimulus and (2) the instrumental contingency between a particular response and stimulus delivery. To our knowledge, the effects of D3-preferring ligands on newresponse acquisition with drug-conditioned reinforcement have not been previously reported. However, new-response acquisition has been used to establish stringently that dopaminergic agonism can enhance water-conditioned reinforcement (Cador et al. 1991; Taylor and Robbins 1984) . Therefore, the present study focused on pramipexole's ability to enhance remifentanilconditioned reinforcement. Experiments were conducted to characterize pramipexole's dose-effect function (experiment 1) and timecourse (experiment 2). To clarify the receptor subtypes involved in pramipexole's effects, pretreatments of the D3-preferring antagonist, SB-277011A, or the D2-preferring antagonist, L-741,626, were given prior to sessions of responding with conditioned reinforcement (experiment 3) or sessions in which yawning and penile erection, two responses previously shown to depend specifically on D3 activity (Collins et al. 2005 (Collins et al. , 2007 ), were measured (experiment 4).
Methods

Subjects
Male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing at least 250 g served as the experimental subjects. Animals were housed individually in a climate controlled facility under a 12-h light-dark cycle (lights on at 7:00 a.m.) and were allowed to acclimate to the facility for at least 7 days before experimental procedures began. All animals had unrestricted access to standard pellet chow and tap water in the home cage. Experimental sessions were conducted 5-7 days/ week during the light phase of the cycle. All experimental groups contained eight rats, except where noted in experiment 2. All studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Research 2011), as adopted and promulgated by the National Institutes of Health, and all experimental procedures were approved by the University of Michigan Committee on the Use and Care of Animals.
Drugs
Remifentanil was obtained from the hospital pharmacy of the University of Michigan Health System (Ultiva brand, GlaxoSmithKline; Uxbridge, UK). Pramipexole was obtained from APAC Pharmaceutical (Columbia, MD). SB-277011A was synthesized by the laboratory of Dr. Shaomeng Wang (University of Michigan, Ann Arbor, MI). L-741,626 was obtained from Tocris Bioscience (Bristol, UK). Remifentanil and pramipexole were dissolved in sterile physiological saline. SB-277011Awas dissolved in a 20 % (w/v) solution of β-cyclodextrin and sterile water. L-741,626 was dissolved in a 5 % (v/v) solution of ethanol and sterile water. Remifentanil injections were delivered IV in a volume of 100 μl/kg. Pramipexole and L-741,626 were injected SC in a volume of 1.0 ml/kg. Due to solubility limitations, SB-277011A was injected SC in volumes of 1.0-3.2 ml/kg.
Surgery
After acclimating to the facility, animals in experiments 1-3 were catheterized to allow for IV drug administration. Catheters were custom-made from polyurethane tubing (MRE-040, Braintree Scientific; Braintree, MA) and Tygon tubing (S-54-HL, Norton Performance Plastics; Akron, OH). Catheterization surgery was performed under ketamine/ xylazine (90:10 mg/kg, IP) anesthesia. The catheter was inserted into the left femoral vein and routed subcutaneously to the scapulae, where it was secured to a Dacron mesh backplate (DC95BS, Instech Laboratories; Plymouth Meeting, PA) and attached to 22 ga stainless steel tubing for externalization. Rats were allowed to recover for at least 5 days following surgery. Catheters were flushed daily with 0.25 ml of heparinized saline (50 U/ml) to ensure patency.
Apparatus
In experiments 1-3, all sessions were conducted in two experimental chambers (ENV-008, Med Associates; St. Albans, VT) controlled by Med-PC IV software (Med Associates). Each experimental chamber was housed in a light-and soundattenuating cubicle and was located in a separate room of the laboratory. The right wall of each chamber contained a white incandescent houselight (ENV-215M, Med Associates) and a sound generator and speaker (ENV-230 and ENV-224AM, Med Associates). Two nose-poke manipulanda with built-in LED stimulus lights (ENV-114BM, Med Associates) could also be inserted into the right wall. When present, the nosepokes were located 2.5 cm above the grid floor and 4 cm from the front wall (right nose-poke) or 4 cm from the rear wall (left nose-poke) of the chamber. The houselight was centered horizontally between the nose-pokes 9 cm above the grid floor. The speaker was located above the right nose-poke 7.5 cm above the grid floor. Blank aluminum panels replaced the nose-pokes when the nose-pokes were removed from the chamber.
Motorized syringe drivers (PHM-107, Med Associates) were located outside of the light-and sound-attenuating cubicles to deliver IV drug injections. Syringes were attached to Tygon tubing (S-54-HL, Norton Performance Plastics), which was connected to a fluid swivel (375/22PS, Instech Laboratories or QCS-D, Strategic Applications Inc.; Lake Villa, IL) and spring tether mounted to a counterbalanced arm.
In experiment 4, animals were observed in transparent plastic chambers (48×23×20 cm), which resembled the animals' home cages, except there was no food, water, or bedding in the observation chambers. Angled mirrors were placed behind the observation chambers to facilitate viewing the animal regardless of its position in the chamber.
Pavlovian conditioning
After recovery from surgery, animals in experiments 1-3 received either "paired" or "random" Pavlovian conditioning (PAV) for five consecutive sessions. During PAV sessions, the nose-pokes were removed from the experimental chambers, and all animals received response-independent IV injections of 3.2 μg/kg/injection remifentanil and response-independent deliveries of a light-noise compound stimulus consisting of houselight illumination and white noise of 80±5 dB (measured at the chamber's center). Injections and stimuli lasted 2.0±0.5 s, depending on the weight of the animal. In paired PAV groups, a single variable time (VT) 3-min (range 0.0-6.0 min) schedule controlled both remifentanil injection and stimulus delivery, and injections and stimuli always cooccurred. In the random PAV control group, remifentanil injection and stimulus delivery were each controlled by independently running VT 3-min schedules; injections and stimuli were not explicitly unpaired. PAV sessions lasted until 20 injections and 20 stimuli were delivered, approximately 60 min. These parameters were chosen based on a previous study of remifentanil-conditioned reinforcement (Bertz and Woods 2013) .
Instrumental acquisition
For all animals in experiments 1-3 (i.e., regardless of PAV type), instrumental acquisition (ACQ) sessions began the day after the conclusion of PAV. For all ACQ sessions, the two nose-pokes were present in the chamber. Responses in the inactive nose-poke had no scheduled consequences. Responses in the active nose-poke produced the light-noise stimulus alone under a modified random ratio 2 schedule: the first response in each session produced the stimulus with a probability of 1.0, whereas each subsequent response in the session produced the stimulus with a probability of 0.5. In each group, the side of the active nose-poke (left vs. right) was counterbalanced across animals. Illumination of the stimulus lights inside both nose-pokes signaled the start of each ACQ session, and both nose-pokes remained illuminated continuously throughout the session. The number and duration of ACQ sessions conducted differed among experiments, as described below. In each experiment, animals were returned to their home cages between pretreatment injection(s) and the start of the session.
In experiment 1 (pramipexole dose-effect function), each group was tested in 14 ACQ sessions (ACQ1-14). ACQ1 lasted 60 min, and no pretreatment injection was given. From ACQ2 to ACQ14, each session lasted 240 min, and a pretreatment injection was given 10 min before the start of each session. The increased session duration was based on the session durations used in previous studies of extinction responding (Collins et al. 2012; De Vries et al. 2002) . After paired PAV, pramipexole (0.1, 0.32, or 1.0 mg/kg) or its vehicle was administered to separate groups of animals on ACQ2-8 and ACQ10-14. On ACQ9, all groups were pretreated with vehicle. A control group was given 0.32 mg/kg pramipexole according to the same schedule after random PAV.
In experiment 2 (pramipexole timecourse), each group was tested in eight ACQ sessions (ACQ1-8). All ACQ sessions lasted 60 min. No pretreatment injection was given before ACQ1. From ACQ2 to ACQ8, animals were injected with either vehicle or 0.32 mg/kg pramipexole either 10 or 190 min before the start of each session, giving four groups: 10-min vehicle (n=4), 190-min vehicle (n=4), 10-min pramipexole (PRAM) (n=6), and 190-min PRAM (n=8).
In experiment 3 (antagonist administration), 10 ACQ sessions (ACQ1-10) were conducted. ACQ1 lasted for 60 min, and no pretreatment injection was given. Session duration increased to 240 min for ACQ2-10. An injection of 0.32 mg/kg pramipexole was given to all animals 10 min before ACQ2-6. ACQ7-10 were the antagonist test sessions, and all animals received two pretreatment injections before each of these sessions: (1) SB-277011A, L-741,626, or their respective vehicles were given 40 min before the start of the session, and (2) 0.32 mg/kg pramipexole or its vehicle was given 10 min before the start of the session. Two groups of animals were tested with L-741,626: a "high dose" group (high L) received vehicle, 0.32 mg/kg, or 3.2 mg/kg, whereas a "low dose" group (low L) received vehicle, 0.1 mg/kg, or 1.0 mg/kg. One group of animals received SB-277011A (SB): vehicle, 5.6 mg/kg, or 56.0 mg/kg. Each antagonist dose was tested for one ACQ session. In each group, antagonist doses were given in either ascending or descending order before 0.32 mg/kg pramipexole. The vehicle+vehicle condition was tested first or last (i.e., on ACQ7 or ACQ10) in each group. This latter condition was included to verify that vehicle+ 0.32 mg/kg pramipexole enhanced responding. Antagonists were classified as D3-vs. D2-preferring, and pretreatment doses and times were selected based on previous work in the laboratory (Collins et al. 2007 (Collins et al. , 2012 .
Observation of yawning and penile erection
In experiment 4, yawning and penile erection were measured in two groups of animals. Yawning was defined as the prolonged (~1 s), wide opening of the mouth followed by rapid closure, whereas penile erection was defined as an emerging, engorged penis, typically followed by upright body posture and genital grooming ). Each animal was observed in one session. At the start of the session, animals were placed individually into the observation chambers and allowed to acclimate to the chamber for 30 min. Separate groups were then injected with vehicle or 56.0 mg/kg SB-277011A. Thirty minutes after antagonist injection, all animals were injected with 0.32 mg/kg pramipexole. Unique yawns and penile erections were counted by a trained observer at the following times after pramipexole injection: 55-70, 115-130, 175-190 , and 235-250 min. These observation periods were chosen to correspond to the final 15 min of the first, second, third, and fourth hours, respectively, of the ACQ sessions used in experiment 3. Animals remained in the observation chambers between injections and among observation periods.
Data analysis
In experiment 1, the mean number of active and inactive nosepokes made in each ACQ session was analyzed in four separate phases, corresponding to when animals did or did not receive pramipexole: ACQ1, ACQ2-8, ACQ9, and ACQ10-14. Analyses were performed using mixed-model ANOVA with factors for manipulandum (active vs. inactive) and, when appropriate, group (i.e., pretreatment dose) and/or session.
If the stimulus served as a conditioned reinforcer, animals should make more active than inactive responses. If pramipexole enhanced the conditioned reinforcing effects of the stimulus, animals receiving pramipexole should make significantly more active responses than vehicle-treated animals. Therefore, if significant effects involving manipulandum and group were found, responding was averaged across sessions to perform two sets of pairwise comparisons: (1) paired t tests were used to compare active vs. inactive responding within groups, and (2) unpaired t tests were used to compare the active and inactive responses of each pramipexole-treated group to the active and inactive responses, respectively, of the vehicletreated group.
To characterize the effects of pramipexole on the intrasession allocation of responding in experiment 1, the active responses made by the animals treated with vehicle or 0.32 mg/kg pramipexole during ACQ2-8 were reanalyzed.
Rates of responding (responses/minute) in each hour (hours 1-4) of each session were calculated and were analyzed using three-way ANOVA with factors for hour, session, and group. Following significant effects of hour and group, the data were averaged across sessions for pairwise comparison of the groups in each hour using unpaired t tests.
In experiment 2, the responses of the vehicle-treated animals were first analyzed using three-way ANOVA with factors for manipulandum, session, and pretreatment interval (10 vs. 190 min). Because no effect of pretreatment interval was significant, the two vehicle groups were combined for subsequent analyses. Responding in ACQ1 and ACQ2-8 was then analyzed separately using mixed-model ANOVA followed by pairwise comparisons as in experiment 1.
In experiment 3, to check that pramipexole did not have a different effect among groups before the start of antagonist administration, the mean active and inactive nose-pokes made in each session from ACQ2-6 were analyzed using three-way ANOVA with factors for manipulandum, session, and group. In the antagonist test sessions, the mean active and inactive nosepokes of each group were analyzed separately using two-way ANOVA with factors for manipulandum and pretreatment condition. Based on a previous study in the laboratory of D3-vs. D2-preferring antagonists (Collins et al. 2012 ) and on the range of doses found to be effective in experiment 1 (i.e., higher doses that produce D2-mediated effects in rats, Collins et al. 2007) , it was hypothesized a priori that both SB-277011A and L-741,626 would attenuate the effects of pramipexole. Therefore, planned comparisons with paired t tests were used to determine if active or inactive responses in the other pretreatment conditions differed from responding on the same manipulandum in the vehicle+0.32 mg/kg pramipexole condition. Finally, to determine if L-741,626 suppressed responding before the stimulus was presented, the latency to the first active response in each antagonist test session was calculated in minutes and then log-transformed to reduce the heterogeneity of variance. If an animal failed to respond, its latency was recorded as 240 min. Mean latencies were then analyzed separately for each group using one-way ANOVA with repeated measures.
In experiment 4, yawns and penile erections were summed to produce a D3-mediated behavioral score for each animal in each observation period. The mean behavioral scores from each observation period were analyzed using mixed-model ANOVA with factors for SB-277011A pretreatment dose and observation period.
Analyses were performed using Prism 5.0 or 6.0 (GraphPad Software; La Jolla, CA) or SPSS Statistics 20.0 (IBM; Armonk, NY). Differences were considered significant when p<.05, two-tailed. Except where noted for experiment 3, the Holm-Bonferonni method was used to correct for multiple pairwise comparisons. Only significant effects are described numerically below. All data are presented graphically as the mean±SEM.
Results
Experiment 1: effects of pramipexole on new-response acquisition for a remifentanil-paired stimulus Figure 1 presents the active and inactive nose-poke responses of rats treated with pramipexole after paired PAV. Panels a and b of Fig. 1 present the active and inactive responses, respectively, made in each of the 14 ACQ sessions. Mean responding in each of the four phases of ACQ is presented in Fig. 1c-f .
In ACQ1 (Fig. 1c) and ACQ9 (Fig. 1e) In ACQ2-8, the first period of pramipexole treatment, animals responded differently in the active vs. inactive nosepokes [manipulandum: F(1,28) = 44.79, p < .001]. The manipulandum × session interaction was not significant. Averaged across sessions (Fig. 1d) (Fig. 1f) , animals in all groups made significantly more active responses than inactive responses [vehicle: t(7)=4.24, p=.011; 0.1 mg/kg: t(7)=4.32, p=.014; 0.32 mg/kg: t(7)=3.69, p=.007; 1.0 mg/kg: t (7) Figure 3 presents the rate of active responding in each hour of ACQ1 and ACQ2-8 by the groups pretreated with vehicle ( Fig. 3a) or 0.32 mg/kg pramipexole (Fig. 3b) Experiment 2: effects of pramipexole exposure without extended ACQ session duration Because pramipexole had a slow onset of effect within the extended (i.e., 240 min long) ACQ sessions in experiment 1, the animals in experiment 2 were given pramipexole with more or less time before the start of shorter (i.e., 60 min long) ACQ sessions in order to determine the sufficiency of extended exposure to pramipexole per se to enhance responding. In the vehicle-treated animals, pretreatment time did not affect responding; therefore, the vehicle groups were combined for Fig. 1 Effects of pramipexole on the acquisition of a novel nosepoke response which produced a stimulus previously paired with remifentanil injection. a, b Session-by-session record of active and inactive responding, respectively, by separate groups of rats (n=8/group) pretreated with pramipexole or vehicle (0.0 mg/kg). c Responding in ACQ1, when no pretreatment was given. d Mean responding in ACQ2-8, when a pretreatment of pramipexole or vehicle was given before each session. e Responding in ACQ9, when all groups received a vehicle pretreatment. f Mean responding in ACQ10-14, when pretreatments of pramipexole or vehicle were resumed. *p<.05; **p<.01; ***p<.001. Significant difference between active and inactive responding either collapsed across groups (for ACQ1 and ACQ9) or within each group (for ACQ2-8 and ACQ10-14). #p<.05; ##p<.01; ###p<.001. Significant difference in responding on the same manipulandum compared to vehicle treatment presentation and analysis. Figure 4 presents the active (Fig. 4a) and inactive (Fig. 4b) nose-poke responses of the vehicletreated animals and animals treated with 0.32 mg/kg pramipexole either 10 or 190 min before the start of the session.
In ACQ1 (Fig. 4c) , before the start of pretreatments, responding did not differ among the groups. The main effect of manipulandum only approached significance [F(1,19) Figure 5a presents the nose-poke responding of the three antagonist pretreatment groups (SB, low L, high L) before the start of antagonist administration. Active responding increased over the course of pramipexole Fig. 2 Nose-poke responses made by rats (n = 8) treated with pramipexole after random PAV, when remifentanil injections and stimulus deliveries were not consistently paired. Responding did not differ significantly between manipulanda or across sessions Figure 5b presents the responses of animals pretreated with SB-277011A. Across pretreatment conditions, animals made more active responses than inactive responses [manipulandum: F(1,7)=32.78, p<.001]. Overall, the effects of antagonist pretreatment condition were not significant. By pairwise comparison to vehicle+0.32 mg/kg pramipexole, animals made significantly fewer active responses only when pretreated with vehicle+vehicle [t(7)=3.32, p=.012]. There were no significant differences in inactive responding. Figure 5c , d presents the responses of the animals pretreated with L-741,626. Animals in the low L group (Fig. 5c) .32 mg/kg pramipexole, animals made significantly fewer active responses when given 1.0 mg/kg L-741,626 +0.32 mg/kg pramipexole [t(7)=2.49, p=.041] or vehicle+vehicle [t(7)= 2.57, p=.036]. There were no significant differences in inactive responding. Animals in the high L group (Fig. 5d) Compared to vehicle+0.32 mg/kg pramipexole, animals made significantly fewer active responses when given 3.2 mg/kg L-741,626+0.32 mg/kg pramipexole [t(7)=3.52, p=.009] or vehicle+vehicle [t(7)=2.64, p=.033]. There were no significant differences in inactive responding. In both the low L group and high L group, pretreatment condition did not affect animals' latency to initiate active responding at the start of the session (data not shown).
Experiment 4: effects of SB-277011A on D3-mediated elicited responses Figure 6 presents the combined number of yawns and penile erections made by animals given 0.32 mg/kg pramipexole after pretreatment with 56.0 mg/kg SB-277011A or its vehicle. Rats made significantly fewer yawns and penile erections when given 56.0 mg/kg SB-277011A [F(1,14)=15.51, p=.001]. No effects involving observation period were significant.
Discussion
The present study characterized the ability of the dopamine D3-preferring agonist, pramipexole, to enhance the conditioned reinforcing effects of a remifentanil-paired stimulus. Whereas previous studies have shown that selective dopamine D2-like receptor agonists can enhance rats' new-response acquisition with food-or water-paired stimuli (Beninger and Ranaldi 1992; Sutton et al. 2001; Wolterink et al. 1993 ), the present experiments provide, to our knowledge, the first demonstration that a selective, direct dopaminergic agonist can enhance the acquisition of responding with drug-conditioned reinforcement. After paired PAV, all groups of animals significantly preferred the active response, which produced the stimulus but never remifentanil, to the inactive response. Compared to vehicle, higher doses of pramipexole significantly increased active responding without changing inactive responding. In contrast, animals treated with pramipexole after random PAV, which provided the same amount of exposure to remifentanil and the stimulus as paired PAV, did not respond differently between the nose-pokes, which still either produced (active response) or did not produce (inactive response) the stimulus alone. Thus, the effects of pramipexole on nose-poking during ACQ depended on not only the instrumental contingency between a particular response and stimulus delivery but also the Pavlovian contingency between the stimulus and remifentanil, as required to conclude that pramipexole changed conditioned reinforcement (Mackintosh 1974, p 234) . Pramipexole enhanced active responding with an inverted U-shaped dose-response function, consistent with previous studies of the effects of the D3-preferring agonist, quinpirole, on new-response acquisition with food-or water-paired stimuli (Beninger and Ranaldi 1992; Wolterink et al. 1993 ). Rather (n=8) when treated with higher doses of L-741,626 prior to pramipexole or treated with vehicle only. *p<.05; **p<.01. Significant difference in responding on the same manipulandum compared to vehicle+0.32 mg/kg PRAM Fig. 6 Effects of SB-277011A or its vehicle (0.0 mg/kg) on yawning and penile erections (PE) by pramipexole-treated animals (n=8/group). **p<.01. Significant main effect of SB-277011A dose than indicating a loss of the stimulus' conditioned reinforcing effects or of pramipexole's response-enhancing effects, the descending limb of the dose-response function likely resulted from an interaction of pramipexole's response-enhancing mechanisms (discussed below) with a response-disrupting mechanism, e.g., pramipexole's locomotor effects. The response-enhancing effects of pramipexole in the present study cannot be attributed only to nonspecific hyperlocomotion, given the importance of animals' Pavlovian histories and the selectivity of changes for the active, but not inactive, response. Nonetheless, pramipexole's locomotor effects may have contributed to the overall shape of the dose-effect function. In the range of doses tested in experiment 1, pramipexole has complex locomotor effects that depend on both dose and time after administration (Chang et al. 2011; Lagos et al. 1998; Maj et al. 1997): broadly, in open-field tests, lower doses produce persistent hypolocomotion, whereas higher doses produce an initial period of hypolocomotion followed by hyperlocomotion. Higher doses of pramipexole can also increase focused behaviors (e.g., sniffing; Chang et al. 2011) . Either locomotor sedation (as observed by Wolterink et al. 1993, p 361) or the eliciting of competing locomotor responses could have interfered with nose-poke responding. The concurrent collection of locomotor measures in future studies of conditioned reinforcement may help resolve this issue.
In characterizing a drug's behavioral effects, it is important to distinguish the contributions of behavioral experience with the drug from exposure to the drug per se (e.g., Jonkman et al. 2012; Zimmer et al. 2014) . Presently, extended exposure to pramipexole without extended exposure to the ACQ session was insufficient to enhance responding after paired PAV. In experiment 1, animals treated with pramipexole showed increases in active responding in the final 60 min of ACQ sessions lasting 240 min (i.e., 190-250 min after pramipexole injection); however, in experiment 2, animals did not show enhanced active responding when given pramipexole 190 min before ACQ sessions lasting only 60 min (i.e., in the same 190-250 min postinjection interval). Therefore, the development of pramipexole's effects over time, both within and across sessions, in experiment 1 was not determined exclusively by pharmacokinetic factors (e.g., slow absorption and/or distribution) or receptor-level changes that can be induced by drug treatment without behavioral testing (e.g., receptor trafficking; Min et al. 2013) . In complement, active responding was not enhanced when animals were exposed to an extended ACQ session without pramipexole pretreatment: in ACQ9 in experiment 1, when animals previously administered pramipexole were given vehicle, and in the vehicle+vehicle condition in experiment 3. Enhanced responding depended on both pramipexole administration and extended ACQ session access.
This pattern focuses attention on the learning mechanisms operating during behavioral testing. Analyzing responding with conditioned reinforcement is complicated by the fact that, by definition, conditioned reinforcement depends on both Pavlovian and instrumental learning (Mackintosh 1974; O'Brien and Gardner 2005; Williams 1994) . For example, Pavlovian extinction has been thought to limit significantly new-response acquisition: each response-contingent presentation of the stimulus necessarily occurs in the absence of the primary reinforcer with which it was originally paired, potentially reducing or eliminating the conditioned reinforcing effects of the stimulus (Mackintosh 1974; Williams 1994) . D3-preferring agonists can attenuate the effects of extinction in other behavioral preparations (Dubrovina and Zinov'eva 2010; Kurylo and Tanguay 2003; Nader and LeDoux 1999) . Therefore, it is possible that pramipexole interfered with the extinction of the remifentanil-stimulus association during ACQ (or the expression of that extinction learning), allowing the "full strength" of the conditioned reinforcer to determine responding. If so, active responding would have increased across ACQ sessions as animals acquired the novel instrumental contingency between the active response and the stimulus, and the reductions in responding when pramipexole was withheld could be attributed to a pramipexole-state dependency of the instrumental acquisition.
Pramipexole may also have impacted instrumental incentive learning processes during ACQ, leading to an increase in the reinforcing efficacy or value of the stimulus (e.g., Collins et al. 2012) . Studies of instrumental reinforcer revaluation using food reinforcement have found that dopaminergic manipulations do not cause or affect reinforcer value changes (Dickinson et al. 2000; Lex and Hauber 2010; Trifilieff et al. 2013; Wassum et al. 2011 ; but see Hitchcott et al. 2007 ). However, more work is needed to understand how drugs, like or unlike foods, act as instrumental incentives (e.g., Hutcheson et al. 2001 ) and to determine whether or not dopamine is involved in the revaluation of drug reinforcers, both primary and conditioned.
Considering the particular dopamine receptor subtypes involved in pramipexole's effects, the present study indicates a significant role for the D2 receptor in remifentanilconditioned reinforcement. At a dose, 1.0 mg/kg, previously shown to have D2-selective effects in vivo (Collins et al. 2007 ), L-741,626, attenuated the responseenhancing effects of pramipexole, mimicking the effects of substituting saline for pramipexole. It is unlikely that this effect was due to general locomotor suppression, as animals' latency to initiate responding at the start of the session was not changed by L-741,626 pretreatment. SB-277011A, in contrast, did not alter the response-enhancing effects of pramipexole. The highest dose of SB-277011A tested presently, 56.0 mg/kg, has been shown to produce D3-selective effects in vivo (Collins et al. 2007 ) and is equal to or larger than doses that have been effective in other, different behavioral tasks involving drug selfadministration and/or drug-paired stimuli (e.g., Cervo et al. 2007; Di Ciano et al. 2003; Higley et al. 2011; Ross et al. 2007 ). Nevertheless, experiment 4 was performed to demonstrate that 56.0 mg/kg of SB-277011A can block responses associated specifically with D3 activity (Collins et al. 2005 (Collins et al. , 2007 following pramipexole administration for a length of time corresponding to the antagonist test sessions of experiment 3. The yawning and penile erection measured in experiment 4 are not necessarily directly related to responding with drug-conditioned reinforcement, but they do provide an important independent measure of SB-277011A's activity at D3 receptors.
The lack of effect of SB-277011A in the present study may be related to the particular training drug (remifentanil) and/or to the particular stimulus function (conditioned reinforcement) under investigation. Whereas SB-277011A can attenuate opioid-conditioned place preference (Ashby et al. 2003) , the effects of D3 antagonism on opioid selfadministration and responding with opioid associated stimuli in operant procedures have not been well established. Far more work has been done in cocaine-or nicotine-trained animals (reviewed by Heidbreder 2013). To resolve this issue, it will be necessary (1) to test D3 antagonists using procedures that can rigorously establish the conditioned reinforcing effects of stimuli paired with these other drugs and (2) to test opioids in the other behavioral preparations (e.g., second order schedules of reinforcement) in which D3 antagonists have been effective.
Whereas the present results do not implicate the D3 receptor in the enhancement of remifentanil-conditioned reinforcement, they are consistent with several pieces of evidence indicating that D2 receptor activity is important for opioid self-administration and responding with opioid-associated stimuli. First, quinpirole can reinstate rats' heroin-trained responding (De Vries et al. 2002) , but does so only at larger doses that have been shown to produce significant D2-mediated effects (i.e., ≥0.1 mg/kg; Collins et al. 2005 Collins et al. , 2007 . Second, D2 receptor knockout mice fail to acquire both morphine self-administration (Elmer et al. 2002) and morphine-conditioned place preference (Maldonado et al. 1997; Smith et al. 2002 ; but see Dockstader et al. 2001) . These latter results also suggest the importance of the training drug, as D2 knockout mice can acquire cocaine self-administration (Caine et al. 2002) and cocaineconditioned place preference (Bello et al. 2011; Smith et al. 2002) . Future studies of the effects of drugassociated stimuli may benefit particularly from more direct comparisons of the effects of D3 vs. D2 receptor manipulations (e.g., Collins et al. 2012) . Ultimately, resolving both the associative learning mechanisms and receptor mechanisms by which dopaminergic manipulations affect drug-conditioned reinforcement may be important to both treating drug abuse disorders and understanding basic learning processes.
